ADC Therapeutics SA (NYSE:ADCT) gapped up prior to trading on Tuesday . The stock had previously closed at $38.68, but opened at $41.98. ADC Therapeutics shares last traded at $40.93, with a volume of 8,922 shares.

ADCT has been the topic of several analyst reports. initiated coverage on shares of ADC Therapeutics in a research note on Tuesday, June 9th. They issued a “buy” rating and a $45.00 target price on the stock. Bank of America started coverage on shares of ADC Therapeutics in a research note on Tuesday, June 9th. They issued a “buy” rating and a $45.00 target price on the stock. Cowen started coverage on shares of ADC Therapeutics in a research report on Tuesday, June 9th. They set an “outperform” rating on the stock. Zacks Investment Research downgraded shares of ADC Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 11th. Finally, Morgan Stanley started coverage on shares of ADC Therapeutics in a research report on Tuesday, June 9th. They set an “overweight” rating and a $53.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $47.67.

The business’s 50-day moving average is $42.86. The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.73.

ADC Therapeutics (NYSE:ADCT) last issued its quarterly earnings data on Tuesday, August 18th. The company reported ($0.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.96) by $0.25. On average, equities analysts forecast that ADC Therapeutics SA will post -4.37 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE purchased a new stake in ADC Therapeutics during the second quarter valued at approximately $164,000. Marshall Wace North America L.P. purchased a new stake in ADC Therapeutics during the second quarter valued at approximately $1,451,000. Artal Group S.A. purchased a new stake in ADC Therapeutics during the second quarter valued at approximately $6,366,000. Principal Financial Group Inc. purchased a new stake in ADC Therapeutics during the second quarter valued at approximately $7,166,000. Finally, WINTON GROUP Ltd purchased a new stake in ADC Therapeutics during the second quarter valued at approximately $10,719,000. 31.06% of the stock is owned by institutional investors and hedge funds.

ADC Therapeutics Company Profile (NYSE:ADCT)

There is no company description available for ADC Therapeutics SA.

Further Reading: How the Dogs of the Dow Strategy Works

Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.